Sowell Financial Services LLC Purchases 9,205 Shares of Bristol Myers Squibb Company $BMY

Sowell Financial Services LLC grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 16.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 66,105 shares of the biopharmaceutical company’s stock after buying an additional 9,205 shares during the period. Sowell Financial Services LLC’s holdings in Bristol Myers Squibb were worth $3,566,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of BMY. Brighton Jones LLC boosted its holdings in shares of Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 2,786 shares in the last quarter. United Bank boosted its holdings in shares of Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after buying an additional 3,277 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 4.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,431 shares of the biopharmaceutical company’s stock valued at $344,000 after buying an additional 292 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $221,000. 76.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on BMY shares. Guggenheim restated a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Barclays started coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price on the stock. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Piper Sandler restated an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Finally, Leerink Partners boosted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Nine analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $61.41.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.09% of the stock is currently owned by insiders.

Bristol Myers Squibb Trading Down 0.5%

Shares of Bristol Myers Squibb stock opened at $59.30 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The firm has a market capitalization of $121.07 billion, a price-to-earnings ratio of 17.19, a PEG ratio of 0.17 and a beta of 0.27. The firm’s 50 day simple moving average is $59.47 and its two-hundred day simple moving average is $52.85.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the previous year, the company posted $1.67 EPS. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.